Table 6. Sensitivity analyses of estimated time from HIV seroconversion to antiretroviral treatment initiation and delay in antiretroviral treatment initiation, Cameroon, 2007–2010.
| Year of ART initiation | Time from HIV seroconversion to ART initiation |
Delay in ART initiation (95% CI) | |
|---|---|---|---|
| Mean years (95% CI) | Median years (IQR) | ||
| Scenario with increase in HIV virulencea | |||
| 2007–2009 | |||
| All | 9.2 (9.0 to 9.3)*** | 8.6 (6.5 to 11.6) | 3.2 (3.0 to 3.4) |
| Women | 9.0 (8.8 to 9.1)*** | 8.4 (6.5 to 11.3) | 3.0 (2.8 to 3.2) |
| Men | 9.6 (9.4 to 9.8)*** | 9.2 (6.8 to 12.3) | 3.6 (3.4 to 3.8) |
| 2010 | |||
| All | 8.6 (8.4 to 8.9)*** | 7.9 (5.6 to 11.3) | 5.2 (4.9 to 5.5)* |
| Women | 8.5 (8.2 to 8.7)*** | 7.8 (5.5 to 11.2) | 5.1 (4.8 to 5.4)* |
| Men | 8.9 (8.5 to 9.3)*** | 8.3 (5.8 to 11.6) | 5.5 (5.0 to 6.0) |
| Scenario with decrease in HIV virulenceb | |||
| 2007–2009 | |||
| All | 11.8 (11.6 to 11.9)*** | 11.2 (8.7 to 14.8) | 3.7 (3.5 to 3.9) |
| Women | 11.6 (11.4 to 11.7)*** | 10.9 (8.6 to 14.4) | 3.5 (3.3 to 3.7) |
| Men | 12.3 (12.0 to 12.6)*** | 11.9 (9.0 to 15.6) | 4.2 (3.9 to 4.5) |
| 2010 | |||
| All | 11.1 (10.9 to 11.4)*** | 10.4 (7.5 to 14.4) | 6.5 (6.2 to 6.8)** |
| Women | 11.0 (10.7 to 11.3)*** | 10.2 (7.4 to 14.3) | 6.3 (5.9 to 6.7)* |
| Men | 11.4 (10.9 to 11.9)*** | 10.8 (7.8 to 14.7) | 6.8 (6.2 to 7.4) |
ART: antiretroviral treatment; CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range; *P < 0.05; **P < 0.02; ***P < 0.0001.
a We assumed 5% lower CD4+ count at HIV seroconversion and 5% higher CD4+ cell count slope.
b We assumed 5% higher CD4+ count at HIV seroconversion and 5% lower CD4+ cell count slope.